Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to give written consent, and who can attend scheduled visits, follow the treatment plan, and complete required tests.
• People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer) confirmed by tissue, cell, or imaging-based testing, following established medical guidelines.
• People whose liver cancer has spread beyond a certain size or number of tumours within the liver (known as "beyond Milan criteria"), but has not spread to areas outside the liver or to lymph nodes — this includes people with no prior treatment, people whose cancer returned more than 2 years after initial treatment, or people whose cancer returned within 2 years under specific tumour size conditions (confirm with trial site).
• People whose liver is still functioning at a manageable level, with a liver scoring measure (Child-Pugh score) of 7 or below, no brain complications from liver disease, and any fluid build-up in the abdomen that is controllable with water tablets.
• People with a general health and activity level score within acceptable ranges (ECOG performance score of 2 or below, or KPS score of 60 or above).
• People who have not received any immunotherapy treatments in the 6 months before enrolling.
• People with adequate bone marrow, liver, and kidney function as measured by blood tests.
• People whose liver condition, based on a standard medical scoring tool, suggests a life expectancy of more than 12 weeks before a potential liver transplant.
• People who have not had another life-threatening cancer outside the liver in the past 5 years.
• People with a history of high blood pressure that is currently well-managed (below 140/90 mmHg) with medication.
• People who agree to use effective contraception throughout the trial and for 6 months after it ends — this applies to both men and women.

Who may not be able to join:

• People whose liver cancer has been confirmed as a different type, such as bile duct cancer, mixed-type liver cancer, or other rare liver cancers.
• People whose cancer has come back but whose original treatment did not achieve complete removal or full remission.
• People with uncontrolled infections, alcoholism or drug dependency, serious heart, lung, or brain conditions, unmanaged psychiatric disorders, severe mental illness, HIV, or active tuberculosis.
• People with severely elevated pressure in the liver's blood vessels that carries a high risk of bleeding, as assessed by the medical team.
• People who have had a bleeding event related to high liver blood pressure in the past 6 months.
• People who have experienced a life-threatening event in the past 6 months, such as a heart attack, unstable chest pain, heart failure, stroke, blood clot in the lungs, or serious bleeding elsewhere.
• People with a severely enlarged spleen, or spleen-related conditions that have caused very low white blood cell or platelet counts.
• People who have had a severe episode of liver-related brain confusion (grade III hepatic encephalopathy), or who require ongoing drainage of fluid from the chest, abdomen, or around the heart.
• People with uncontrolled high blood pressure, or a history of hypertensive crisis or high blood pressure affecting the brain.
• People with severe high blood pressure in the lungs that cannot be managed with medication.
• People with serious blood-clotting problems, or who are currently receiving or require ongoing blood-thinning or clot-dissolving treatment.
• People with a history of autoimmune conditions such as rheumatoid arthritis, lupus, psoriasis, Crohn's disease, or ulcerative colitis.
• People who have had a major surgical procedure within 4 weeks before the first dose, or who have had a severe allergic reaction to any of the study medications.
• People who are pregnant or breastfeeding.
• People with severe psychiatric or psychological disorders.

Important: Always verify eligibility with the trial site directly before applying.